Galectins and their ligands: amplifiers, silencers or tuners of the inflammatory response?
Gabriel A. Rabinovich(Universidad de Buenos Aires), Stefano Iacobelli(CTI BioPharma (Italy)), Fu‐Tong Liu(University of Southern California), Roberto Paganelli(Saint Camillus International University of Health and Medical Sciences), Linda G. Baum(University of California, Los Angeles), Nicola Tinari(University of Chieti-Pescara), Clara Natoli(Kliniken Essen-Mitte)
Cited by 530
Related Papers
Turning 'sweet' on immunity: galectin–glycan interactions in immune tolerance and inflammation
|Nature reviews. Immunology|2009|895
Galectins: structure, function and therapeutic potential
|Expert Reviews in Molecular Medicine|2008|861
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|724
Increased cytokine production in mononuclear cells of healthy elderly people
|European Journal of Immunology|1993|650
Pathogenesis of tendinopathies: inflammation or degeneration?
|Arthritis Research & Therapy|2009|570